MRD in CLL

CE / CME

Assessing Measurable Residual Disease in Chronic Lymphocytic Leukemia

Pharmacists: 0.75 contact hour (0.075 CEUs)

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Nurses: 0.75 Nursing contact hour

Released: August 30, 2022

Expiration: August 29, 2023

Nichole Fisher
Nichole Fisher, RN, BSN
Anthony J. Perissinotti
Anthony J. Perissinotti, PharmD, BCOP
Jennifer A. Woyach
Jennifer A. Woyach, MD

Activity

Progress
1
Course Completed

In this focused activity, Jennifer Woyach, MD; Nichole Fisher, RN, BSN; and Anthony Perissinotti, PharmD, BCOP, discuss the latest information on measurable residual disease (MRD) testing and its clinical use in the care of patients with chronic lymphocytic leukemia (CLL).

Clinical Care Options plans to measure the educational impact of this activity, and some questions in this activity will be asked twice: once before the discussion that informs the best choice and then again after that specific discussion. Your responses will be aggregated for analysis, but your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following question.

If you are a practicing healthcare professional, how many patients with CLL do you provide care for in a typical month?

When counseling a patient with CLL who asks you about the role of MRD testing in CLL management, which of the following would you tell them?